SynthesisMedicine2017
Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis.
Synthesis in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Cephalic and ocular manifestations of EBV-associated plasmablastic lymphoma: Clinical and radiological response to bortezomib, EPOCH, and intrathecal methotrexate.Radiology case reports · 2024Article
- Plasmablastic lymphoma: current knowledge and future directions.Frontiers in immunology · 2024Review
- Proliferative glomerulonephritis with monoclonal IgG Lambda deposits caused by plasmablastic lymphoma: a case report.BMC nephrology · 2023Article
- A challenging diagnosis of plasmablastic lymphoma: importance of integrating morpholgy immunohistochemistry and flow cytometry findings (case report).The Pan African medical journal · 2023Article
- Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China.BMC medicine · 2022Article
- Oral and para-oral lymphomas: a 10-year multi-center retrospective study in Egypt with time series analysis and forecasting to 2030.BMC oral health · 2022Article
- Tibial Plasmablastic Lymphoma in a HIV-Negative Child: A Novel Extraoral Localisation.Case reports in hematology · 2022Article
- Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.International journal of hematology · 2021Article
- A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion.The Kaohsiung journal of medical sciences · 2021Article
- The characteristic computed tomography findings of pulmonary B-cell non-Hodgkin's lymphoma and their role in predicting patient survival.Quantitative imaging in medicine and surgery · 2021Article
- Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.Frontiers in medicine · 2021Article
- Light chain cast nephropathy caused by plasmablastic lymphoma of the bladder.Clinical nephrology. Case studies · 2021Article
- Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review.Journal of hematology · 2020Article
- Article
- Plasmablastic lymphoma as a manifestation of the human immunodeficiency virus: Case report.Journal of clinical and experimental dentistry · 2020Article
- Intraoral plasmablastic lymphoma as a primary oral manifestation: A case report and review of literature.Journal of oral and maxillofacial pathology : JOMFP · 2020Article
- Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis.Case reports in hematology · 2019Article
- Plasmablastic lymphoma in Malawi.Infectious agents and cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmablastic lymphoma (PBL) is a B-cell malignancy associated with human immunodeficiency virus (HIV). PBL could also influence the HIV-negative patients. The study aimed to identify prognostic factors for survival among Chinese PBL patients. MATERIALS AND
methodsEligible patients from literature and Peking Union Medical College Hospital (PUMCH) were included in this study. Clinical characteristics and immunophenotypic data were extracted. Kaplan-Meier curve was used to describe the survival status. Cox regression was used for multivariate analysis.
resultsA total of 60 Chinese PBL patients were included, including 54 patients from 36 published articles and 6 new patients that have not been reported. The median overall survival was 7 months (95% confidence interval 3.853-10.147 months). An overwhelming majority (79.31%) of the included cases were Ann Arbor stage IV patients. All the Chinese PBL patients were HIV-negative; 46.81% were Epstein-Barr virus-positive. CD38, CD138, or MUM1 was positively expressed in more than 80% of patients; CD20 expression was also found in 22.03% of cases. Kaplan-Meier curve revealed obvious differences in patient survival between patients in primary stages and advanced stages, as well as between patients with kidney involvement and those without kidney involvement. Cox regression analysis indicated that stage and age were 2 prognostic factors for patient survival.
conclusionsAdvanced stage might be associated with poor prognosis among PBL HIV-negative patients in Chinese.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.